PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
8786250-1	1995	Procainamide administration often results in excessively high serum N-acetylprocainamide (NAPA) concentrations and subtherapeutic serum procainamide concentrations.	Procainamide	0-12	NSF attachment protein alpha	Homo sapiens	90-94	
8786250-2	1995	Inhibition of N-acetylation of procainamide may prevent accumulation of excessive NAPA while maintaining therapeutic serum procainamide concentrations.	Nitrogen	14-15	NSF attachment protein alpha	Homo sapiens	82-86	
8786250-2	1995	Inhibition of N-acetylation of procainamide may prevent accumulation of excessive NAPA while maintaining therapeutic serum procainamide concentrations.	Procainamide	31-43	NSF attachment protein alpha	Homo sapiens	82-86	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	4-Aminobenzoic Acid	21-25	NSF attachment protein alpha	Homo sapiens	84-88	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	4-Aminobenzoic Acid	21-25	NSF attachment protein alpha	Homo sapiens	124-128	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	4-Aminobenzoic Acid	21-25	NSF attachment protein alpha	Homo sapiens	124-128	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	4-Aminobenzoic Acid	21-25	NSF attachment protein alpha	Homo sapiens	124-128	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	Procainamide	46-58	NSF attachment protein alpha	Homo sapiens	84-88	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	Procainamide	46-58	NSF attachment protein alpha	Homo sapiens	124-128	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	Procainamide	46-58	NSF attachment protein alpha	Homo sapiens	124-128	
8786250-10	1995	However, concomitant PABA administration with procainamide resulted in increases in NAPA AUC0-00 and t1/2 and reductions in NAPA Ke, procainamide acetylation (NAPA formation) clearance, and NAPA renal clearance.	Procainamide	46-58	NSF attachment protein alpha	Homo sapiens	124-128	
8786250-11	1995	Although PABA inhibits metabolic conversion of procainamide to NAPA, it also impairs the renal clearance of NAPA (but not procainamide) in healthy subjects.	4-Aminobenzoic Acid	9-13	NSF attachment protein alpha	Homo sapiens	63-67	
8786250-11	1995	Although PABA inhibits metabolic conversion of procainamide to NAPA, it also impairs the renal clearance of NAPA (but not procainamide) in healthy subjects.	4-Aminobenzoic Acid	9-13	NSF attachment protein alpha	Homo sapiens	108-112